Martin K, Trouche D, Hagemeier C, Sørensen T S, La Thangue N B, Kouzarides T
Wellcome/CRC Institute, Cambridge, UK.
Nature. 1995 Jun 22;375(6533):691-4. doi: 10.1038/375691a0.
The MDM2 proto-oncogene is found amplified in a variety of tumours. The oncogenic capacity of the MDM2 protein is attributed to its ability to bind the p53 tumour-suppressor protein and mask its transcriptional activation potential. Here we show that MDM2 makes a functional contact with two cooperating transcription factors, E2F1 and DP1 (refs 4,5), which are involved in S-phase progression. MDM2 contacts the activation domain of E2F1 using residues conserved in the activation domain of p53. However, in contrast to its repression of p53 activity, MDM2 stimulates the activation capacity of E2F1/DP1. These results indicate that MDM2 not only releases a proliferative block by silencing the tumour suppressor p53, it also positively augments proliferation by stimulating the S-phase inducing transcription factors E2F1/DP1.
MDM2原癌基因在多种肿瘤中被发现存在扩增现象。MDM2蛋白的致癌能力归因于其与p53肿瘤抑制蛋白结合并掩盖其转录激活潜能的能力。在此我们表明,MDM2与两个协同作用的转录因子E2F1和DP1(参考文献4、5)发生功能性接触,这两个转录因子参与S期进程。MDM2利用p53激活域中保守的残基与E2F1的激活域接触。然而,与它对p53活性的抑制作用相反,MDM2刺激E2F1/DP1的激活能力。这些结果表明,MDM2不仅通过使肿瘤抑制因子p53失活来解除增殖阻滞,还通过刺激S期诱导转录因子E2F1/DP1来正向增强增殖。